© Reuters. Anika’s Monovisc OK’d in Australia
- The Australian Therapeutic Goods Administration approves Anika Therapeutics ‘ (NASDAQ:ANIK) MONOVISC (hyaluronan) for the treatment of pain associated with osteoarthritis of all synovial joints, including the hip and knee.
- MONOVISC is commercially available in over 20 countries.
- Now read: Not A Falling Knife: Synergy Pharmaceuticals’ Drop Makes For A Great Buy